Dr. Diana Tichy

Area of Work

• Design and analysis of clinical trials (phase II to IV)
• Statistical leadership of clinical (research) projects
• Prediction modeling for clinical data
• Analysis of microarray data
• Simulation of high-dimensional data (Bootstrap applications, plasmode data sets)

Education and Background

• Biometrician for clinical trials (phase II to IV), collaboration with the GMALL and the GMMG-study group since 2017
• Postdoctoral Fellow, Division of Biostatistics at the DKFZ since 2013
• Dr. rer. nat., Faculty of Mathematics and Informatics, University of Würzburg, 2012
• 2007-2012, Research Assistant, Institut of Mathematics / University Hospital at the University of Würzburg
• Diploma in Mathematics, University of Würzburg, 2007

Selected Publications

Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Düring J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N., Huhn S., Kriegsmann K.,
Luntz S.P., Holderried T.A., Trautmann-Grill K., Gezer D., Klaiber-Hakimi M., Müller M., Khandanpour C., Knauf, W. et al.: Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part
1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Hematology 9(11), e810 -e821 (2022).

Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, Ko YD, Reinhardt HC, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny U, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H Weisel KC: Isatuximab, carlzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia 2022

Klein EM, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann HW, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab MS, Blau IW, Haenel M, Scheid C, Goldschmidt H: Prognostic Impact of Serum Free Light Chain Ratio Normaliza-tion in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers 2021.

Tavakoli A, Kuder T, Tichy D, Radtke J, Görtz M, Schütz V, Stenzinger A, Hohenfellner M, Schlemmer H, Bonekamp D: Measured Multi-point Ultra-High b-Value Diusion MRI in the Assessment of MRI-Detected Prostate Lesions. Journal of Investigative Radiology 2021.

Goldschmidt and Mai et al: Response-adapted lenalidomide maintenance in newly-diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 2020.

Bonsack M, Hoppe S, Winter J, Tichy D, Zeller C, Küpper MD, Schitter E, Blatnik R, Riemer A: Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding dataset. Cancer Immunology Research (in review) 2018.

Groß J, Nattenmüller J, Hemmer S, Tichy D, Goldschmidt H, Bertsch U, Delorme S, Kauczor HU, Hillengass J, Merz M: Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma. Subgroup analysis of the prospective GMMG MM5 trial. Oncotarget 2017, 8(40):68460-68471.

Tichy D, Pickl J, Benner A, Sueltmann H: Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets. Briefings in Bioinformatics 2018, 19(5):918-929.

Bickelhaupt S, Paech D, Kickingereder P, Steudle F, Lederer W, Daniel H, Götz M, Gählert N, Tichy D, Wiesenfarth M, Laun FB, Maier-Hein K, Schlemmer HP, Bonekamp D: Malignant suspicious breast lesions predicted by a radiomic signature from contrast agent-free diffusion MRI. Journal of Magnetic Resonance Imaging 2017, 46(2):604-616.

Wolf MB, Edler C, Tichy D, Röthke MC, Schlemmer HP, Herfarth K, Bonekamp D: Di_usion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique. Journal of Magnetic
Resonance Imaging 2017, 46(3):850-860.

Pickl JM, Tichy D, Kuryshev V, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, et al: Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget 2016, 7(37): 59589-59603.

Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, Goidts V: Targeting atypical protein kinase C iota reduces viability in glioblastoma Stem-like cells via a notch signaling mechanism. International Journal
of Cancer 2016, 139(8):1776-1787.

Burth S, Kickingereder P, Eidel P, Tichy D, Bonekamp D, Weberling L, Wick A, Löw S, Hertenstein A, Nowosielski M, Schlemmer HP, Wick W, Bendszus M, Radbruch A: Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro Oncology 2016, 18(12):1673-1679.